Clinical Trial Update: Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating melphalan plus bortezomib as conditioning before autologous and allogeneic stem cell transplants in multiple myeloma has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Melphalan + Bortezomib

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2018-10-12